Sector News

Roche to buy U.S. cancer drugmaker Ignyta for $1.7 billion

December 26, 2017
Life sciences

Roche Holding agreed to acquire U.S. biotech Ignyta for $1.7 billion, following Bayer in buying into a class of experimental cancer drugs that home in on a specific mutation across many types of tumors.

Ignyta investors will get $27 a share in cash, the companies said in a statement Friday. That’s 74% higher than Thursday’s closing price. Both companies’ boards agreed to the deal.

Roche’s purchase comes about five weeks after Bayer signed a $1.55 billion licensing deal for Loxo Oncology’s larotrectinib, an experimental medicine similar to Ignyta’s entrectinib. Roche has said it will focus on small deals like Ignyta to build out its portfolio. The Swiss company, the world’s biggest maker of cancer drugs, is facing a critical transition as its three top-selling medicines lose patent protection.

San Diego-based Ignyta’s entrectinib is being tested in patient trials that, if successful, could be the basis for applications with regulators to sell the drug. Roche said it aims to complete the purchase in the first half of 2018.

Citigroup advised Roche on the deal, while Sidley Austin provided legal advice. Ignyta used bankers from BofA Merrill Lynch and J.P. Morgan Securities with Latham & Watkins as legal counsel.

Roche shares fell 0.1% to 246.50 Swiss francs at 9:10 a.m. in Zurich, valuing the company at 213 billion francs ($215 billion).

Ignyta was founded in 2011 by University of California, San Diego researcher Gary Firestein and Jonathan Lim, the former chief executive officer of Halozyme Therapeutics Inc.

Source: Bloomberg via Fortune

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend